Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence

Liquid biopsies (circulating tumor DNA—ctDNA testing) are increasingly being utilized in clinical trials as well as practice for the detection of cancer, monitoring of tumor genomic abnormalities, response to treatment and early detection of relapse/recurrence. Here, we present a challenging case wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Soyano, Aixa E., Baldeo, Candice, Kasi, Pashtoon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372543/
https://www.ncbi.nlm.nih.gov/pubmed/30788289
http://dx.doi.org/10.3389/fonc.2019.00046
Descripción
Sumario:Liquid biopsies (circulating tumor DNA—ctDNA testing) are increasingly being utilized in clinical trials as well as practice for the detection of cancer, monitoring of tumor genomic abnormalities, response to treatment and early detection of relapse/recurrence. Here, we present a challenging case where liquid biopsy was used to confirm an early recurrence of pancreatic cancer where acquisition of tissue was not safe or feasible on more than one occasion.

Ejemplares similares